Press Release

<< Back
CVS Caremark Reports Fourth Quarter and Full Year Results; 2012 Guidance Raised to Reflect Anticipated First Quarter Benefit of Prescription Transfers From Walgreens

WOONSOCKET, R.I., Feb. 8, 2012 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) today announced revenues, operating profit and net income for the three months and year ended December 31, 2011.

Fourth Quarter Year-Over-Year Highlights:

  • Net revenues increased 15.2% to a record $28.3 billion, with Pharmacy Services up 32.4% and Retail Pharmacy up 4.0%
  • Retail Pharmacy segment same stores sales increased 2.5%
  • Adjusted EPS of $0.89, up 16.2% excluding $0.03 per share tax benefit in prior year; GAAP diluted EPS from continuing operations of $0.84

Full Year Highlights:

  • Net revenues increased 11.8% to a record $107.1 billion, with Pharmacy Services up 24.9% and Retail Pharmacy up 3.9%
  • Retail Pharmacy segment same store sales increased 2.3%
  • Adjusted EPS of $2.80, up 5.9% excluding $0.03 per share tax benefit in prior year; GAAP diluted EPS from continuing operations of $2.59
  • Generated free cash flow of $4.6 billion; cash flow from operations of $5.9 billion

2012 Guidance:

  • Full-year Adjusted EPS of $3.18 to $3.28; GAAP diluted EPS from continuing operations of $2.96 to 3.06  
  • First quarter Adjusted EPS from continuing operations of $0.61 to $0.63; GAAP diluted EPS from continuing operations of $0.55 to $0.57
  • Expect to generate full year free cash flow of $4.6 to $4.9 billion; cash flow from operations of $6.2 to $6.4 billion  

Revenues

Net revenues for the three months ended December 31, 2011, increased 15.2% or $3.7 billion, to $28.3 billion, up from $24.6 billion in the three months ended December 31, 2010. For the year ended December 31, 2011, total revenue increased 11.8% or $11.3 billion, to $107.1 billion, compared to $95.8 billion for the year ended December 31, 2010.

Revenues in the Pharmacy Services segment increased 32.4% to $15.9 billion in the three months ended December 31, 2011. This increase was primarily associated with the addition of a previously-announced, long-term contract with Aetna, Inc., as well as new activity resulting from our acquisition of the Medicare prescription drug business of Universal American Corp. ("UAM Medicare Part D Business") in the second quarter of 2011. Pharmacy network claims processed during the three months ended December 31, 2011 increased 46.0% to 193.0 million, compared to 132.2 million in the prior year period. The increase in pharmacy network claims was primarily due to the Company's recent acquisition of the UAM Medicare Part D Business, the addition of the Aetna contract, and an increase in covered lives in our existing Medicare Part D Business. Mail choice claims processed during the three months ended December 31, 2011 increased approximately 8.1% to 17.8 million compared to 16.5 million in the prior year period. The increase in the mail choice claim volume was primarily driven by the addition of the Aetna contract. For the year ended December 31, 2011, total revenue in the Pharmacy Services segment increased 24.9% to $58.9 billion, compared to $47.1 billion in the year ended December 31, 2010.

Revenues in the Retail Pharmacy segment increased 4.0% to $15.5 billion in the three months ended December 31, 2011. Same store sales increased 2.5% over the prior year period. Pharmacy same store sales rose 3.6% on a standard calendar basis. Calendar day shifts in the fourth quarter of 2011, which had one additional Saturday and one fewer Friday compared with the same period in 2010, negatively impacted pharmacy same store sales by 50 basis points. Additionally, pharmacy same store prescription volumes rose 2.1% when 90-day scripts are counted as one script. When converting 90-day scripts into 3 scripts, our same store prescription volumes increased 4.4% in the quarter. Pharmacy same store sales include a positive impact from Maintenance Choice® of approximately 160 basis points on a net basis (i.e., a positive impact of approximately 190 basis points on a gross basis, net of approximately 30 basis points from the conversion of 30-day prescriptions at retail to 90-day prescriptions under the Maintenance Choice program). Pharmacy same store sales were negatively impacted by approximately 235 basis points due to recent generic introductions. Front store same store sales increased 0.1% in the three months ended December 31, 2011. For the year ended December 31, 2011, total revenue in the Retail Pharmacy segment increased 3.9% to $59.6 billion, compared to $57.3 billion in the year ended December 31, 2010. Same store sales increased 2.3% for the year ended December 31, 2011 over the prior year.

For the three months ended December 31, 2011, the generic dispensing rate increased approximately 220 basis points to 75.0% in our Pharmacy Services segment and 210 basis points to 75.9% in our Retail Pharmacy segment, compared to the prior year period.

Income from Continuing Operations Attributable to CVS Caremark

Income from continuing operations attributable to CVS Caremark for the three months ended December 31, 2011, increased $79.0 million to $1.1 billion, compared with $1.0 billion during the three months ended December 31, 2010. The increase in income from continuing operations was primarily driven by improved operating profit in both our Pharmacy Services and Retail Pharmacy segments. Adjusted earnings per share from continuing operations attributable to CVS Caremark ("Adjusted EPS") for the three months ended December 31, 2011 and 2010 was $0.89 and $0.79, respectively. Excluding the $0.03 per share tax benefit recognized in the fourth quarter of 2010, Adjusted EPS rose 16.2% in the fourth quarter of 2011. Adjusted EPS excludes $114 million and $108 million of intangible asset amortization related to acquisition activity in the three months ended December 31, 2011 and 2010, respectively. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the three months ended December 31, 2011 and 2010 was $0.84 and $0.74, respectively.

Income from continuing operations attributable to CVS Caremark for the year ended December 31, 2011 increased $66 million, or 1.9%, to $3.5 billion, compared to $3.4 billion in the prior year. Adjusted earnings per share from continuing operations attributable to CVS Caremark, which excludes $452 million and $427 million of intangible asset amortization related to acquisition activity for the year ended December 31, 2011 and 2010, was $2.80 and $2.68, respectively. Excluding the $0.03 per share tax benefit recognized in the fourth quarter of 2010, Adjusted EPS rose 5.9% for the year ended December 31, 2011. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the year ended December 31, 2011 was $2.59, compared to $2.49 in the prior year.

President and Chief Executive Officer, Larry Merlo, said, "2011 was a year of great accomplishment for CVS Caremark. We executed successfully on a number of key initiatives across the Company and reported solid financial results, delivering on our promises. Our retail business continued to post strong top- and bottom-line results, and our PBM enjoyed strong revenue growth, another very successful selling season, and great progress on several important initiatives. These include the development of a number of unique, new integrated offerings as well as the streamlining initiative, which is expected to produce cumulative savings from 2011 through 2015 of more than $1 billion. We generated $4.6 billion in free cash for the year, exceeding our goal, and returned more than $3.5 billion to our shareholders in the form of dividends and share repurchases."

Mr. Merlo continued, "As we close the chapter on 2011, we are optimistic that we can deliver even better results in 2012. We have the right people, the right assets, and the right plans in place to continue to reinvent pharmacy and benefit from the changing health care landscape. Our retail business continues to execute successfully, while our PBM is poised to return to healthy operating profit growth in 2012. Our substantial cash generation capabilities should enable us to continue to drive shareholder value now and in the years ahead."

Discontinued Operations

On November 1, 2011, the Company completed the sale of its TheraCom, L.L.C. ("TheraCom") subsidiary to AmerisourceBergen Corporation for $250 million, subject to a working capital adjustment. TheraCom is a provider of commercialization support services to the biotech and pharmaceutical industry. The TheraCom business has historically been part of the Company's Pharmacy Services segment. The results of the TheraCom business are presented as discontinued operations and have been excluded from both continuing operations and segment results for all periods presented. The Company recognized a $53 million pre-tax gain and a $37 million after tax loss on the sale of TheraCom. The after tax loss was caused by the income tax treatment of TheraCom's nondeductible goodwill.

In connection with certain business dispositions completed between 1991 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens 'n Things which filed for bankruptcy in 2008. The Company's income (loss) from discontinued operations includes lease-related costs which the Company believes it will likely be required to satisfy pursuant to its Linens 'n Things lease guarantees.

Real Estate Program

During the three months ended December 31, 2011, the Company opened 24 new retail drugstores and closed one retail drugstore. In addition, the Company relocated five retail drugstores. As of December 31, 2011, the Company operated 7,404 locations, included in which were 7,327 retail drugstores, 30 onsite pharmacies, 31 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail order pharmacies in 44 states, the District of Columbia and Puerto Rico.

Guidance

The Company raised its earnings guidance for the first quarter and full year 2012 to reflect the anticipated benefit to first quarter results of approximately $0.03 per share from the impasse between Walgreens and Express Scripts. The guidance adjustment only reflects the potential estimated benefit if the stalemate continues through the end of the first quarter, and does not contemplate any potential benefit beyond the first quarter. The Company currently expects to deliver Adjusted EPS of $3.18 to $3.28 and GAAP diluted earnings per share from continuing operations of $2.96 to $3.06 per share in 2012. The Company now expects the Retail Pharmacy segment's operating profit to increase between 8.5% and 10.5%, up from a range of 7% to 9%, while the Pharmacy Services segment's operating profit growth is still expected to increase between 11% and 15%. In light of the Company's expectation for additional working capital improvements, the Company also raised its 2012 free cash flow guidance by $300 million, to a range of $4.6 billion to $4.9 billion. Further, the Company now expects to generate cash flow from operations in 2012 in the range of $6.2 billion to $6.4 billion. These 2012 guidance estimates assume the completion of $3 billion in share repurchases, the amount remaining in the share repurchase program authorized in 2011 by CVS Caremark's board of directors.

Teleconference and Webcast

The Company will be holding a conference call today for the investment community at 8:30 am (EST) to discuss its quarterly results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

About the Company

CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

-- Tables Follow --

CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Income

(Unaudited)



Three Months Ended


Year Ended


December 31,


December 31,

In millions, except per share amounts

2011


2010


2011


2010









Net revenues

$  28,317


$   24,589


$  107,100


$    95,778

Cost of revenues

22,762


19,135


86,539


75,559

Gross profit

5,555


5,454


20,561


20,219

Operating expenses

3,598


3,693


14,231


14,082

Operating profit

1,957


1,761


6,330


6,137

Interest expense, net

147


136


584


536

Income before income tax provision

1,810


1,625


5,746


5,601

Income tax provision

711


605


2,258


2,179

Income from continuing operations

1,099


1,020


3,488


3,422

Income (loss) from discontinued operations, net of tax

(36)


5


(31)


2

Net income

1,063


1,025


3,457


3,424

Net loss attributable to noncontrolling interest

1


1


4


3

Net income attributable to CVS Caremark

$  1,064


$     1,026


$      3,461


$      3,427









Income from continuing operations attributable to CVS Caremark:








Income from continuing operations

$  1,099


$      1,020


$     3,488


$     3,422

Net loss attributable to noncontrolling interest

1


1


4


3

Income from continuing operations attributable to CVS Caremark

$  1,100


$      1,021


$     3,492


$  3,425









Basic earnings per common share:








   Income from continuing operations attributable to CVS Caremark

$  0.84


$        0.75


$       2.61


$        2.51

   Income (loss) from discontinued operations attributable to CVS Caremark

(0.03)



(0.02)


   Net income attributable to CVS Caremark

$  0.82


$        0.75


$      2.59


$        2.51

   Weighted average basic common shares outstanding

1,302


1,363


1,338


1,367









Diluted earnings per common share:








Income from continuing operations attributable to CVS Caremark

$  0.84


$         0.74


$  2.59


$       2.49

   Income (loss) from discontinued operations attributable to CVS Caremark

(0.03)



(0.02)


   Net income attributable to CVS Caremark

$  0.81


$        0.75


$      2.57


$        2.49

   Weighted average diluted common shares outstanding

1,310


1,372


1,347


1,377









Dividends declared per common share

$   0.1250


$   0.0875


$  0.5000


$   0.3500




CVS CAREMARK CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)



December 31,

In millions, except per share amounts

2011


2010

Assets:




   Cash and cash equivalents

$  1,413


$  1,427

   Short-term investments

5


4

   Accounts receivable, net

6,047


4,925

   Inventories

10,046


10,695

   Deferred income taxes

503


511

   Other current assets

580


144

       Total current assets

18,594


17,706

   Property and equipment, net

8,467


8,322

   Goodwill

26,458


25,669

   Intangible assets, net

9,869


9,784

   Other assets

1,155


688

       Total assets

$  64,543


$  62,169





Liabilities:




   Accounts payable

$  4,370


$  4,026

   Claims and discounts payable

3,487


2,569

   Accrued expenses

3,293


3,070

   Short-term debt

750


300

   Current portion of long-term debt

56


1,105

       Total current liabilities

11,956


11,070

   Long-term debt

9,208


8,652

   Deferred income taxes

3,853


3,655

   Other long-term liabilities

1,445


1,058

   Commitments and contingencies




   Redeemable noncontrolling interest

30


34





Shareholders' equity:




Preferred stock, par value $0.01: 0.1 shares authorized; none issued or     outstanding


Common stock, par value $0.01: 3,200 shares authorized; 1,640 shares issued and 1,298 shares outstanding at December 31, 2011 and 1,624 shares issued and 1,363 shares outstanding at December 31, 2010

16


16

Treasury stock, at cost: 340 shares at December 31, 2011 and 259 shares at December 31, 2010

(11,953)


(9,030)

Shares held in trust: 2 shares at December 31, 2011 and December 31, 2010

(56)


(56)

Capital surplus

28,126


27,610

Retained earnings

22,090


19,303

Accumulated other comprehensive loss

(172)


(143)

   Total shareholders' equity

38,051


37,700

Total liabilities and shareholders' equity

$  64,543


$  62,169




CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)



Year Ended


December 31,

In millions

2011


2010

Cash flows from operating activities:




   Cash receipts from customers

$    97,688


$       94,503

   Cash paid for inventory and prescriptions dispensed by retail network pharmacies

(75,148)


(73,143)

   Cash paid to other suppliers and employees

(13,635)


(13,778)

   Interest received

4


4

   Interest paid

(647)


(583)

   Income taxes paid

(2,406)


(2,224)

Net cash provided by operating activities

5,856


4,779





Cash flows from investing activities:




   Purchases of property and equipment

(1,872)


(2,005)

   Proceeds from sale-leaseback transactions

592


507

   Proceeds from sale of property and equipment

4


34

   Acquisitions (net of cash acquired) and other investments

(1,441)


(177)

   Purchase of available-for-sale investments

(3)


   Sale or maturity of available-for-sale investments

60


1

   Proceeds from sale of subsidiary

250


Net cash used in investing activities

(2,410)


(1,640)





Cash flows from financing activities:




   Increase (decrease) in short-term debt

450


(15)

   Proceeds from issuance of long-term debt

1,463


991

   Repayments of long-term debt

(2,122)


(2,103)

   Dividends paid

(674)


(479)

   Derivative settlements

(19)


(5)

   Proceeds from exercise of stock options

431


285

   Excess tax benefits from stock-based compensation

21


28

   Repurchase of common stock

(3,001)


(1,500)

   Other

(9)


Net cash used in financing activities

(3,460)


(2,798)

Net increase (decrease) in cash and cash equivalents

(14)


341

Cash and cash equivalents at the beginning of the year

1,427


1,086

Cash and cash equivalents at the end of the year

$  1,413


$            1,427


Reconciliation of net income to net cash provided by operating activities:




   Net income

$  3,457


$  3,424

   Adjustments required to reconcile net income to net cash provided by operating activities:




           Depreciation and amortization

1,568


1,469

           Stock-based compensation

135


150

           Gain on sale of subsidiary

(53)


           Deferred income taxes and other non-cash items

144


30

           Change in operating assets and liabilities, net of effects of acquisitions:




               Accounts receivable, net

(748)


532

               Inventories

607


(352)

               Other current assets

(420)


(4)

               Other assets

(49)


(210)

               Accounts payable and claims and discounts payable

1,128


(40)

               Accrued expenses

85


(176)

               Other long-term liabilities

2


(44)

Net cash provided by operating activities

$  5,856


$  4,779




Adjusted Earnings Per Share

(Unaudited)


For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.


The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.


The following is a reconciliation of income before income tax provision to adjusted earnings per share:





Three Months Ended


Year Ended


December 31,


December 31,

In millions, except per share amounts

2011


2010(2)


2011


2010(2)









Income before income tax provision

$  1,810


$     1,625


$  5,746


$    5,601

Amortization

114


108


452


427

Adjusted income before income tax provision

1,924


1,733


6,198


6,028

Adjusted income tax provision(1)

756


644


2,436


2,345

Adjusted income from continuing operations

1,168


1,089


3,762


3,683

Net loss attributable to noncontrolling interest

1


1


4


3

Adjusted income from continuing operations attributable to CVS Caremark

$      1,169


$     1,090


$      3,766


$    3,686

Weighted average diluted common shares outstanding

1,310


1,372


1,347


1,377

Adjusted earnings per share from continuing operations attributable to CVS Caremark(3)

$        0.89


$       0.79


$        2.80


$       2.68










(1) The adjusted income tax provision is computed using the effective income tax rate from the consolidated statement of income.

(2) The adjusted results for the three months and year ended December 31, 2010 have been revised to reflect the results of TheraCom as discontinued operations.

(3) The adjusted earnings per share from continuing operations attributable to CVS Caremark includes the impact of approximately $35 million and $47 million, or $0.03 per diluted share, of previously unrecognized tax benefits that were recognized in the three months and year ended December 31, 2010, respectively.



Free Cash Flow

(Unaudited)


The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).


The following is a reconciliation of net cash provided by operating activities to free cash flow:






Year Ended



December 31,

In millions


2011


2010






Net cash provided by operating activities


$  5,856


$    4,779

   Subtract:  Additions to property and equipment


(1,872)


(2,005)

   Add:  Proceeds from sale-leaseback transactions


592


507

Free cash flow


$      4,576


$      3,281









Supplemental Information

(Unaudited)


The Company evaluates its Pharmacy Services and Retail Pharmacy segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:





In millions

Pharmacy
Services
Segment(1)


Retail
Pharmacy
Segment


Corporate
Segment


Intersegment
Eliminations(2)


Consolidated
Totals











Three Months Ended










   December 31, 2011:










       Net revenues

$             15,874


$          15,493


$          --


$            (3,050)


$       28,317

       Gross profit

1,016


4,608


--


(69)


5,555

       Operating profit (loss)

724


1,453


(151)


(69)


1,957

   December 31, 2010(3):










       Net revenues

11,995


14,897


--


(2,303)


24,589

       Gross profit

855


4,642


--


(43)


5,454

       Operating profit (loss)

599


1,372


(167)


(43)


1,761

Year Ended










   December 31, 2011:










       Net revenues

58,874


59,599


--


(11,373)


107,100

       Gross profit

3,279


17,468


--


(186)


20,561

       Operating profit (loss)

2,220


4,912


(616)


(186)


6,330

   December 31, 2010(3):










       Net revenues

47,145


57,345


--


(8,712)


95,778

       Gross profit

3,315


17,039


--


(135)


20,219

       Operating profit (loss)

2,361


4,537


(626)


(135)


6,137




(1) Net revenues of the Pharmacy Services segment include approximately $1.9 billion and $1.6 billion of retail co-payments for the three months ended December 31, 2011 and 2010, respectively, as well as $7.9 billion and $6.6 billion of retail co-payments for the year ended December 31, 2011 and 2010, respectively.

(2) Intersegment eliminations relate to two types of transactions: (i) Intersegment revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services segment customers, through the Company's intersegment activities (such as the Maintenance Choice™ program), elect to pick-up their maintenance prescriptions at Retail Pharmacy segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. Beginning in the fourth quarter of 2011, the Maintenance Choice eliminations reflect all discounts available for the purchase of mail order prescription drugs. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $0.7 billion and $0.5 billion for the three months ended December 31, 2011 and 2010, respectively, and $2.6 billion and $1.8 billion for the year ended December 31, 2011 and 2010, respectively; gross profit and operating profit of $69 million and $43 million for the three months ended December 31, 2011 and 2010, respectively, and $186 million and $135 million for the year ended December 31, 2011 and 2010, respectively.

(3) The results of the Pharmacy Services segment for the three months and year ended December 31, 2010 have been revised to reflect the results of TheraCom as discontinued operations.



Supplemental Information

(Unaudited)


Pharmacy Services Segment


The following table summarizes the Pharmacy Services segment's performance for the respective periods:



Three Months Ended


Year Ended


December 31,


December 31,

In millions

2011


2010(4)


2011


2010(4)









Net revenues

$ 15,874


$ 11,995


$ 58,874


$   47,145

Gross profit

1,016


855


3,279


3,315

   Gross profit % of net revenues

6.4%


7.1%


5.6%


7.0%

Operating expenses

292


256


1,059


954

    Operating expense % of net revenues

1.8%


2.1%


1.8%


2.0%

Operating profit

724


599


2,220


2,361

    Operating profit % of net revenues

4.6%


5.0%


3.8%


5.0%









Net revenues(1):








   Mail choice(2)

$ 4,901


$    4,149


$ 18,616


$  16,159

   Pharmacy network(3)

10,924


7,766


40,040


30,681

   Other

49


80


218


305

Pharmacy claims processed(1):








   Total

210.8


148.7


774.6


584.7

   Mail choice(2)

17.8


16.5


70.6


64.1

   Pharmacy network(3)

193.0


132.2


704.0


520.6

Generic dispensing rate(1):








   Total

75.0%


72.8%


74.1%


71.5%

   Mail choice(2)

66.1%


62.9%


64.9%


61.3%

   Pharmacy network(3)

75.8%


73.9%


75.0%


72.7%

Mail choice penetration rate

20.8%


26.1%


22.3%


25.8%


(1) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.

(2) Mail choice is defined as claims filled at a Pharmacy Services' mail facility, which include specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.

(3) Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity.

(4) The results of the Pharmacy Services segment for the three months and year ended December 31, 2010 have been revised to reflect the results of TheraCom as discontinued operations.



EBITDA and EBITDA per Adjusted Claim

(Unaudited)


The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. We define EBITDA per adjusted claim as EBITDA divided by adjusted pharmacy claims. Adjusted pharmacy claims normalize the claims volume statistic for the difference in average days' supply for mail and retail claims. Adjusted pharmacy claims are calculated by multiplying 90-day claims (the majority of total mail claims) by 3 and adding the 30-day claims. EBITDA can be reconciled to operating profit, which we believe to be the most directly comparable GAAP financial measure.


The following is a reconciliation of operating profit to EBITDA for the Pharmacy Services segment:





Three Months Ended


Year Ended


December 31,


December 31,

In millions, except per adjusted claim amounts

2011


2010(1)


2011


2010(1)









Operating profit

$  724


$  599


$  2,220


$  2,361

Depreciation and amortization

116


98


433


389

EBITDA

840


697


2,653


2,750

Adjusted claims

243.9


178.8


905.6


701.4

EBITDA per adjusted claim

$  3.45


$  3.89


$  2.93


$  3.92


(1) The results of the Pharmacy Services segment for the three months and year ended December 31, 2010 have been revised to reflect the results of TheraCom as discontinued operations.



Supplemental Information

(Unaudited)


Retail Pharmacy Segment


The following table summarizes the Retail Pharmacy segment's performance for the respective periods:



Three Months Ended


Year Ended


December 31,


December 31,

In millions

2011


2010


2011


2010









Net revenues

$15,493


$14,897


$59,599


$57,345

Gross profit

4,608


4,642


17,468


17,039

   Gross profit % of net revenues

29.7%


31.2%


29.3%


29.7%

Operating expenses

3,155


3,270


12,556


12,502

    Operating expense % of net revenues

20.4%


22.0%


21.1%


21.8%

Operating profit

1,453


1,372


4,912


4,537

    Operating profit % of net revenues

9.4%


9.2%


8.2%


7.9%









Net revenue increase:








   Total

4.0%


3.1%


3.9%


3.6%

   Pharmacy

4.9%


3.0%


4.4%


4.1%

   Front store

2.1%


3.1%


3.0%


2.6%

Same store sales increase:








   Total

2.5%


1.7%


2.3%


2.1%

   Pharmacy

3.6%


2.0%


3.1%


2.9%

   Front store

0.1%


1.0%


0.8%


0.5%

Generic dispensing rate

75.9%


73.8%


75.6%


73.0%

Pharmacy % of total revenues

67.7%


67.1%


68.3%


68.0%

Third party % of pharmacy revenue

97.9%


97.5%


97.8%


97.4%

Retail prescriptions filled

168.9


163.7


657.8


636.3




Adjusted Earnings Per Share Guidance

(Unaudited)


The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.





Year Ending

In millions, except per share amounts

December 31, 2012





Income before income tax provision

$  6,239


$  6,441

Amortization

460


460

Adjusted income before income tax provision

6,699


6,901

Adjusted income tax provision

2,616


2,695

Adjusted income from continuing operations

4,083


4,206

Net loss attributable to noncontrolling interest

3


3

Adjusted income from continuing operations attributable to CVS Caremark

$  4,086


$  4,209

Weighted average diluted common shares outstanding

1,284


1,284

Adjusted earnings per share from continuing operations attributable to CVS Caremark

$  3.18


$  3.28




Free Cash Flow Guidance

(Unaudited)


The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.





Year Ending

In millions

December 31, 2012





Net cash provided by operating activities

$  6,195


$  6,420

   Subtract:  Additions to property and equipment

(2,145)


(2,075)

   Add:  Proceeds from sale-leaseback transactions

500


600

Free cash flow

$  4,550


$  4,945




SOURCE CVS Caremark Corporation

Investors, Nancy Christal, Senior Vice President, Investor Relations, +1-914-722-4704; or Media, Eileen H. Boone, Senior Vice President, Corporate Communications & Community Relations, +1-401-770-4561

Share This